That sounds reasonable MJplay. Also, if UNVC/AGRiMED submitted their product right away for FDA review, they may have beaten the competition before the flood of mislabeled products came to market. We just don't know that answer. I suspect it is reasonable to assume the "blank" transdermal patches marketed by Merck through MilliporeSigma could be used for the UNVC patch (they are said to be the best on the market and they are already approved for medical clinical trials). There does seem to be some connection, but exactly what we do not know, and in my opinion we just cannot win an argument saying anything other than that. So why bother?